MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

Search

Charles River Laboratories International Inc

Fechado

SetorSaúde

175.38 3.52

Visão Geral

Variação de preço das ações

24h

Atual

Mín

174.06

Máximo

179.34

Indicadores-chave

By Trading Economics

Rendimento

-332M

-277M

Vendas

-11M

994M

Margem de lucro

-27.816

Funcionários

18,300

EBITDA

730K

198M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+21.44% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

359M

8.3B

Abertura anterior

171.86

Fecho anterior

175.38

Sentimento de Notícias

By Acuity

24%

76%

78 / 349 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Charles River Laboratories International Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

8 de abr. de 2026, 20:44 UTC

Ganhos

Costco Reports 11% Growth in March Sales

8 de abr. de 2026, 23:51 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

8 de abr. de 2026, 23:51 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Talks to End Iran War -- Market Talk

8 de abr. de 2026, 23:36 UTC

Conversa de Mercado
Notícias Principais

Gold Edges Lower on Likely Technical Correction -- Market Talk

8 de abr. de 2026, 22:56 UTC

Conversa de Mercado

Ramelius Resources May Downgrade Cost Guidance This Month -- Market Talk

8 de abr. de 2026, 22:45 UTC

Conversa de Mercado

Constellation Brands Points to Continuing Challenges Among Hispanic Consumers -- Market Talk

8 de abr. de 2026, 22:17 UTC

Conversa de Mercado

Applied Digital Says Its Holding Out for Quality Customers -- Market Talk

8 de abr. de 2026, 21:52 UTC

Notícias Principais

A Closer Look at Iran's 10 Demands -- and Which the U.S. Might Accept -- Update

8 de abr. de 2026, 21:24 UTC

Ganhos

FedEx Freight Aims for 12% Profit Growth. How That Compares to the Leader. -- Barrons.com

8 de abr. de 2026, 21:01 UTC

Notícias Principais

Oil Prices Tumble Despite Conflicting Reports About the Strait of Hormuz -- Barrons.com

8 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

8 de abr. de 2026, 20:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Oracle Is Expressing No Opinion and Is Neutral as to Whether Stockholders Should Tender Their Shrs in Response to TRC's Offer >ORCL

8 de abr. de 2026, 20:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Oracle Does Not Endorse TRC's Mini-Tender Offer or the Offer Documentation >ORCL

8 de abr. de 2026, 20:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Oracle: Offer Represents Less Than 0.04% of Outstanding Common Stk >ORCL

8 de abr. de 2026, 20:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Oracle: TRC Offer Is to Purchase Up to 1M Shrs of Common Stk at $140.50/Shr in Cash >ORCL

8 de abr. de 2026, 20:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Oracle Received Notice of Unsolicited Mini-Tender Offer by TRC Dated March 24 >ORCL

8 de abr. de 2026, 20:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Oracle Responds to TRC Cap Mini-Tender Offer

8 de abr. de 2026, 20:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

8 de abr. de 2026, 20:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Intel Corp.: Repurchased 49% Equity Interest in JV Related to Intel's Fab 34 in Ireland >INTC

8 de abr. de 2026, 20:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Intel Corp.: $14.2B Repurchase Price Financed with Cash on Hand and a Bridge Loan of $6.5B >INTC

8 de abr. de 2026, 20:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Intel Corp.: Repurchased JV Stake From Apollo-Managed Funds and Affiliates >INTC

8 de abr. de 2026, 19:44 UTC

Ganhos

These Companies Pay 5% Dividend Yields, and They're Hiking Them Too -- Barrons.com

8 de abr. de 2026, 19:16 UTC

Conversa de Mercado

Hogs Follow Cutout Prices Lower -- Market Talk

8 de abr. de 2026, 19:02 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

8 de abr. de 2026, 19:02 UTC

Conversa de Mercado

Oil Futures Plunge as Cease-Fire Raises Hopes for Restored Supply -- Market Talk

8 de abr. de 2026, 18:58 UTC

Conversa de Mercado

U.S. Natural Gas Futures Fall in Line With Slump in Oil -- Market Talk

8 de abr. de 2026, 18:51 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

8 de abr. de 2026, 18:51 UTC

Conversa de Mercado

Levi Strauss CEO Says Expanded Offerings, DTC Focus Are Working -- Market Talk

8 de abr. de 2026, 18:14 UTC

Notícias Principais

Fed Minutes Suggest a Lengthy Iran War Could Lead to Rate Hikes -- Barrons.com

8 de abr. de 2026, 18:05 UTC

Notícias Principais

Oil Prices Continue to Tumble After Cease-Fire Despite Slow Reopening of Strait of Hormuz -- Barrons.com

Comparação entre Pares

Variação de preço

Charles River Laboratories International Inc Previsão

Preço-alvo

By TipRanks

21.44% parte superior

Previsão para 12 meses

Média 205.89 USD  21.44%

Máximo 265 USD

Mínimo 175 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

8

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

117.16 / 144.77Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

78 / 349 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat